Methadone-Associated Mortality:
Report of a National Assessment

Part 7. References and Bibliography

Appel PW. Joseph H, Richman BL. Causes and rates of death among methadone maintenance patients before and after the onset of the HIV/AIDS epidemic. Mt Sinai J Med. 2000;67(5-6):444-451.

Associated Press. Overdose increases linked to methadone. Stuart News (Stuart, Florida). October 4, 2002.

Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology. 2001;34(1):188-193.

Backmund M, Meyer K, Zwehl W, Nagengast O, Eichenlaub D. Myocardial infarction associated with methadone and/or dihydrocodeine. Eur Addict Res. 2001a;7(1):37-39.

Baden MM. Evaluation of deaths in methadone users. Leg Med Annu. 1978;127-31.

Baden MM. Methadone related deaths in New York City. Int J Addict. 1970;5(3):489-498.

Ballesteros MF, Budnitz DS, Sanford CP, Gilchrist J, Agyekum GA, Butts J. Increase in deaths due to methadone in North Carolina [research letter]. JAMA. 2003;290(1):40.

Barrett DH, Luk AJ, Parrish RG, Jones TS. An investigation of medical examiners cases in which methadone was detected, Harris County, Texas, 1987-1992. J Forensic Sci, JFSCA. 1996;41(3):442-448.

Barton WI. Deaths involving methadone: A statistician's view. Drug Forum. 1975;4(2):139-158.

Bartu EE, Popescu A, Heutt KF, Hansson R, Plumley N. Methadone-related deaths in Western Australia 1993-99. Aust NZ J Pub Health. 2002;26(4):364-370.

Bell J, Zador D. A risk-benefit analysis of methadone maintenance treatment. Drug Saf. 2000;22(3)179-190.

Belluck P. Methadone, once the way out, suddenly grows as killer drug. New York Times (National Edition). New York Times. February 9, 2003A: 1,20.

Belluck P. Overdoses and deaths from abuse of drug methadone are up. New York Times. February 2, 2003B.

Belluck P. Recently for drug abusers, methadone has become a double-edged sword. New York Times (National Edition). February 9, 2003C: 20.

Bendavid, N. Survey of drugs in Cook County: 333,000 labeled hard-core users. Chicago Tribune. December 12, 1997;sec 1:1.

Bittar P, Piguet V, Kondo-Oestreicher J, et al. Methadone induced long QTc and "torsade de pointe." Swiss Medical Forum (Forum Med Suisse). 2002(Apr 10, Suppl 8):36S. [Abstract P244.]

Borron SW, Monier C, Risede P, Baud FJ. Interaction of opiates with benzodiazepines in overdoses. J Toxicology:Clin Toxicology. 2001;39(3):212.

Bowler GM, Galloway DW, Meiklejohn BH, and Macintyre CC. Sharp fall in blood pressure after injections of heparin containing chlorbutanol. Lancet. 1986;1:848-849.

Brown FM, Griffiths PS. P450 Guide: Comprehensive Enzymatic Drug Metabolism Reference. 2nd ed. Montgomery, AL: P450Guide.com; 2000.

Bruera E. Opioid rotation, methadone urged for hard-to-treat cancer pain. Presentation at 14th international meeting of MASCC. In: Oncology News International. 2002;11(12):55.

Cairns A, Roberts IS, Benbow EW. Characteristics of fatal methadone overdose in Manchester, 1985-94. BMJ. 1996;313(7052):264-265.

Caplan YH, Ottinger WE, Crooks CR. Therapeutic and toxic drug concentrations in post mortem blood: A six year study in the State of Maryland. J Anal Toxicol. 1983;7(5):225-230.

Caplehorn JRM. Deaths in the first two weeks of maintenance treatment in NSW in 1994: Identifying cases of iatrogenic methadone toxicity. Drug and Alcohol Review. 1998;17:9-18.

Caplehorn JRM, Drummer OH. Mortality associated with New South Wales methadone programs in 1994: Lives lost and saved. Med J Aust. 1999;170(3):104-109.

CDHAG (Commonwealth Department of Health and Aged Care). Induction and Stabilisation of Patients Onto Methadone. Monograph Series No. 39. Canberra: Commonwealth of Australia; 2000. Available at http://www.health.gov.au.

Chang A, Emmel DW, Rossi GC, Pasternak GW. Methadone analgesia in morphine-insensitive CXBK mice. Eur J Pharm. 1988;351:189-191.

Codd E, Shank R, Schupsky J, Raffia R. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995;274:1263-1270.

Clark JC, Milroy CM, Forrest ARW. Deaths from methadone use. J Clin For Med. 1995;2:143-144.

COMPA (New York State Committee of Methadone Program Administrators). Regarding Methadone Treatment and Other Pharmacotherapies: A Review. New York, NY: COMPA; revised 1999. See also: http://www.compa-ny.org.

Concool B, Smith H, Stimmel B. Mortality rates of persons entering methadone maintenance: A seven-year study. Am J Drug Alcohol Abuse. 1979;6(3):345-353.

Cone EJ, Fant RV, Rohay JM. Oxycodone involvement in drug abuse deaths: A DAWN-base classification scheme applied to an oxycodone postmortem database containing over 1000 cases. J Analyt Tox. 2003;27:57-67.

Cozza KL, Armstrong SC. The Cytochrome P450 System: Drug Interaction Principles for Medical Practice. Washington, DC: American Psychiatric Publishing, Inc.;2001.

D'Aunno T, Pollack HA. Changes in methadone treatment practices: Results from a national panel study, 1988-2000. JAMA. 2002 Aug 21;288(7):850-6.

Davis AM, Inturrisi CE. d-Methadone blocks morphine tolerance and N-Methyl-D-Aspartate (NMDA)-induced hyperalgesia. J. Pharmacol Exp Ther. 1999;289:1048-1053.

Davoli M, Perucci CA, Forastiere F, et al. Risk factors for overdose mortality: A case-control within a cohort of intravenous drug users. Int J Epidemiol. 1993;22(2):273-277.

Dole VP, Foldes F, Trigg H, et al. Methadone poisoning. NYS J Med. 1971;71:541-543.

Dole VP. Implications of methadone maintenance for theories of narcotic addiction. JAMA. 1988;260:3025-3029.

Dorsey JS. Serum methadone levels and optimal dosing in methadone maintained patients. Poster presented at: American Association for the Treatment of Opioid Dependence Conference; April 13-16, 2003; Washington, DC. Poster P9.

Drasch G, Quitterer D, Roider G, Von Meyer L. The enantioselective detection of L- and D-methadone in blood samples from living and deceased addicts [German, abstract in English]. Rechtsmedizin. 2000;10(5):170-175.

Drummer OH, Opeskin K, Syrjanen M, Cordner SM. Methadone toxicity causing death in ten subjects starting on a methadone maintenance program. Am J Forensic Med Pathol. 1992;13(4):346-350.

Drummer OH, Syrjanen M, Opeskin K, Cordner SM. Deaths of heroin addicts starting on a methadone maintenance programme. Lancet. 1990;335(8681):108.

Drummer OH. The toxicology of methadone and its involvement in sudden death. In: 35th Annual TIAFT (The International Association of Forensic Toxicologists) Conference. Padua, Italy; 1997. Abstract 020.

Eap CB, Bourquin M, Martin J-L, et al. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Dru Alcohol Dep. 2000;6(11):47-54.

Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. Clin Pharmacokin. 2002;41(14):1153-1193.

Eap CB, Déglon J-J, Baumann P. Pharmacokinetics and pharmacogenetics of methadone: Clinical relevance. Heroin Add & Rel Clin Probl 1999;1(1):19-34.

Eap CB, Finkbeiner T, Gastpar M, Schebaum N, Bertschy G, Baumann P. High inter-individual variability of methadone enantiomer blood levels to dose ratios [letter]. Arch Gen Psychiatry 1988;55:89-90.

Eastwood JA. Methadone poisoning in children. SOFT-TIAFT 1998 (Society of Forensic Technologists-The International Association of Forensic Toxicologists) Albuquerque, New Mexico; October 7, 1998. Scientific Session 1.

Editorial. Medicine or menace? The Washington Times. February 19, 2003.

Editorial. Methadone overdoses: Abuse of drug spreading so let's restrict the amount. Portland Press Herald (Portland, Maine). September 18, 2002.

Ehlers S. U.S. Congress ponders anti-methadone bill [press release]. Washington, DC: Drug Policy Foundation; February 19, 1999.

English DR, Holman CDJ, Milne E, et al. The quantification of drug-caused morbidity and mortality in Australia, 1995 edition. Canberra: Commonwealth Department of Human Services and Health. AGPS. 1995:539-542.

Ettinger DS, Vitale PJ, Trump DL. Important clinical pharmacologic considerations in the use of methadone in cancer patients. Cancer Treat Rep. 1979;63(3):457-459.

Federal Register. Narcotic drugs in maintenance and detoxification treatment of narcotic dependence; Repeal of current regulations and proposal to adopt new regulations. Federal Register. July 22, 1999;64(140):39809-39857. 21 CFR Part 291; 42 CFR Part 8. Available from the Federal Register Online via GPO at: http://www.access.gpo.gov/su_docs. Accessed August 1, 1999.

Federal Register. Opioid drugs in maintenance and detoxification treatment of opiate addiction; Final rule. 2001 (Jan 17);66(11):4085. 42 CFR Part 8.

FDLE (Florida Department of Law Enforcement). 2002 Interim Report of Drugs Identified in Deceased Persons by Florida Medical Examiners. November 2002. Available at: http://www.fdle.state.fl.us/publications/examiner_drug_report_2002.pdf.

Fingerhut LA, Cox CS. Poisoning Mortality, 1985-1995. Pub Health Rep. 1998;113(3):218-233

Flanagan RJ, Rooney C. Recording acute poisoning deaths. Forensic Sci Int. 2002;128:3-19.

Foster DJR, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 1999;47:403-412.

Frost JL. Commentary on: Oxycodone involvement in drug abuse deaths: A DAWN-base classification scheme applied to an oxycodone postmortem database containing over 1000 cases. J Analyt Tox. 2003;27:67.

GAO (General Accounting Office). Methadone maintenance: some treatment programs are not effective; greater Federal oversight needed. Report to the chairman, Select Committee on Narcotics Abuse and Control, House of Representatives. Washington, DC: U.S. General Accounting Office; 1990. Pub# GAO/HRD-90-104.

Gardner R, Methadone misuse and death by overdosage. Br J Addict. 1970; 65(2):113-118.

Gearing FR, Schweitzer MD. An epidemiologic evaluation of long-term methadone maintenance treatment for heroin addiction. Am J Epidemiology. 1974;100:101-111.

Gfroerer J, Penne M, Pemberton M, Folsom R. Substance abuse treatment need among older adults in 2020: The impact of the aging baby-boom cohort. Drug Alcohol Depend. 2003;69(2):127-135.

Glauser FL, Downie RL, Smith WR. Electrocardiographic abnormalities in acute heroin overdosage. Bull Narc. 1977;29(1):85-89.

Goldstein A, Herrera J. Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up. Drug Alcohol Depend. 1995;40(2):139-150.

Gordon NB. The functional potential of the methadone maintained person. CDRWG Monograph #2. Chemical Dependency Research Working Group: The New York State Office of Alcoholism and Substance Abuse Services. December 1994:43-46.

Gorman AL, Elliott KJ, Inturrisi CE. The d- and l- isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord, Nerurosci Lett. 1997;223: 5-8.

Gourevitch MN, Hartel D, Tenore P, et al. Three oral formulations of methadone. A clinical and pharmacodynamic comparison. J Subst Abuse Treat. 1999;17(3):237-241.

Gottheil E, Sterling RC, Weinstein SP. Diminished illicit drug use as a consequence of long-term methadone maintenance. J Addict Dis. 1993;12(4):45-57.

Green H, James RA, Gilbert JD, Harpas P, Byard RW. Methadone maintenance programs - A two-edged sword? Amer J For Med Path. 2000;21(4):359-361.

Greene MH, Luke JL, DuPont RL. Opiate overdose deaths in the District of Columbia. II. Methadone-related fatalities. J Forensic Sci. 1974;19(3):575-584.

Greenfield L, Fountain D. Influence of time in treatment and follow-up duration on methadone treatment outcomes. J Psychopath Behavioral Assess. 2000;22(4):353-364.

Haberman PW, Noble JA, DuFour MC. Alcohol use in combination with cocaine, heroin, and methadone by medical examiner cases. J Stud Alcohol. 1995;56:344-347.

Hampton CT. Long QT syndrome: more common than you thought. Clin Rev. 2003;13(1):40-46.

Hanzlick R. Death registration: history, methods, and legal issues. J Forensic Sci. 1997;42(2):265-269.

Hanzlick R, Hunsacker III JC, Davis GJ. A Guide for Manner of Death Classification. 1st Edition. St. Louis, MO: National Association of Medical Examiners; February 2002.

Harding-Pink, D. Deaths associated with methadone. J Toxicol Clin Exp. 1991;11(1):31-49.

Harding-Pink D. Opioid toxicity. Lancet. 1993;341:665-666.

Heinemann A, Iwersen-Bergmann S, Stein S, Schmoldt A, Puschel K. Methadone-related fatalities in Hamburg 1990-1999: Implications for quality standards in maintenance treatment? Forensic Sci Int. 2000;113(1-3):449-455.

Heroin abuse and addiction. National Institutes on Drug Abuse (NIDA) Research Report Series. 1997 (October). NIH Pub# 97-4165.

Horrigan FT. Methadone block of neuronal K current. Biophysical J. 1990;57:515A. Abstract W-Pos392.

Hser Y-I, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry. 2001:58:503-508.

Huber A, Ling W, Fradis J, Charuvastra VC. Comparison of the effects of methadone and LAAM on the electrocardiogram. Poster presented at: College of Problems of Drug Dependence (CPDD) 63rd Annual Scientific Meeting, Phoenix, AZ, June 20, 2001. Also in: Huber A, Ling W, Fradis J, Charavastra VC. Comparison of the effects of methadone and LAAM on the electrocardiogram [abstract]. Drug Alcohol Depend. 2001;63:S70.

Huidobro F, Tamayo L, Contreras E. Effects of methadone on the action of catecholamines in isolated preparations. Arch Int Pharmacodyn Ther. 1971;192:168-178.

Inturrisi CE, Verebely K. A gas-liquid chromatographic method for the quantitative determination of methadone in human plasma and urine. J Chrmatogr. 1972a;65:361-369.

Inturrisi CE, Verebely K. The levels of methadone in the plasma in methadone maintenance. Clin Pharm Ther. 1972b;13(5 part 1):633-637.

Joseph H, Appel P. Historical perspectives and public health issues. In: Parrino MW, chair. State Methadone Treatment Guidelines. Treatment Improvement Protocol (TIP) Series 1. Rockville, MD: U.S. Department of Health and Human Services; Center for Substance Abuse Treatment;1993:11-24 DHHS Pub# (SMA) 93-1991.

Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): A review of historical and clinical issues. Mt Sinai J Med. 2000;67(5-6):347-364.

Joseph H, Woods JS eds. Methadone Treatment Works: A Compendium for Methadone Maintenance Treatment. CDRWG Monograph Series #2. Chemical Dependency Research Working Group: The New York State Office of Alcoholism and Substance Abuse Services. December 1994. Available at: http://users.rcn.com/nama.interport/mono2.htm. Accessed May 23, 2002.

Kallan JE. Drug abuse-related mortality in the United States: Patterns and correlates. Amer J Drug Alcohol Abuse. 1998;24(1):103-117.

Karch SB. Stephens BG. Toxicology and the pathology of deaths related to methadone: Retrospective review. West J Med. 2000;172:11-14.

Katchman AN, McGroary KA, Kilborn MJ, Kornick CA, Manfredi PL, Woosley RL, Ebert SN. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K⁺ currents. J Pharm Exp Ther. 2002;303(3):688-694.

Kauffman JF, Woody GE. Matching Treatment to Patient Needs in Opioid Substitution Therapy. Treatment Improvement Protocol (TIP) Series 20. Rockville, MD: U.S. Department of Health and Human Services; Center for Substance Abuse Treatment;1995. DHHS Pub# (SMA) 95-3049.

Kocheril AG, Bokhari SA, Batsford WP, Sinusas AJ. Long QTc and torsades de pointes in human immunodeficiency virus disease. Pacing Clin Electrophysiol. 1997;20(11):2810-2816.

Kramer T. Side effects and therapeutic effects. Medsacape Gen Med. 2003;5(1). Available at http://www.medscape.com.

Krantz MJ, Lewkowiez L, Hays H, et al. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002;137:501-504.

Kreek MJ. A personal retrospective and prospective viewpoint. In: Parrino MW. State Methadone Treatment Guidelines. Treatment Improvement Protocol (TIP) Series 1. Rockville, MD: U.S. Department of Health and Human Services; Center for Substance Abuse Treatment;1993:133-143. DHHS Pub# (SMA) 93-1991.

Kreek MJ, Gutjahr CL, Garfield JW, Bowen DV, Field FH. Drug interactions with methadone. Ann NY Acad Sci. 1976;281:350-370.

Kreek MJ, Hachey DL, Klein PD. Stereoselective disposition of methadone in man. Life Sci. 1979;24:925-932.

Kreek MJ. Medical safety and side effects of methadone in tolerant individuals. JAMA. 1973a;223:665-668.

Kreek MJ. Plasma and urine levels of methadone. NY State J Med. 1973b;73(23):2773-2777.

Kreek MJ. Rationale for maintenance pharmacotherapy of opiate dependency. In: O'Brien CP, Jaffe JH. Addictive States. New York, NY: Raven Press, Ltd.; 1992:205-229.

Kringsholm B. Deaths among drug addicts in Denmark in 1968-1986. Forensic Sci Int. 1988;38(1-2):139-149.

Kringsholm B, Kaa E, Steentoft A, Worm K, Simonsen KW. Deaths among drug addicts in Denmark in 1987-1991. Forensic Sci Int. 1994;67(3):185-195.

Kung H-C, Hanzlick R, Spitler JF. Abstracting data from medical examiner/coroner reports: Concordance among abstractors and implications for data reporting. J Forensic Sci. 2001;46(5):1126-1131.

La Harpe R, Fryc O. Fatalities associated with methadone administration in the Geneva canton (1987-1993). Arch Kriminol. 1995;196(1-2):24-29.

Leavitt SB. Does methadone maintenance treatment affect heart health? Addiction Treatment Forum: Special Report (peer reviewed). June 2001. Available at: http://www.atforum.com.

Leavitt SB, Shinderman M, Maxwell S, Eap CB, Paris P. When "enough" is not enough: New perspectives on optimal methadone maintenance dose. Mt Sinai J Med. 2000;67(5-6):404-411.

Lee CH, Berkowitz BA. Calcium antagonist activity of methadone, l-acetylmethadol and l-pentazocine in the rat aortic strip. J Pharmacol Exp Ther. 1977;202(3):646-653.

Lehder DM, Arria A, Artigiani EE, Wish ED. Alcohol and drug-related overdose deaths in Maryland: 1997-2001. College Park, MD; Center for Substance Abuse Research (CESAR), University of Maryland: November 2002. Available at http://www.dewsonline.org.

Leshner AI. Drug abuse research helps curtail the spread of deadly infectious diseases. NIDA Notes. 1999;14(2):3-4. NIH Pub# 99-3478.

Litovitz TL, Klein-Schwartz W, Rodgers GC, et al. 2001 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Amer J Emergency Med. 2002;20(5):391-452.

Lobert S. Methadone may be a useful alternative for cancer pain. Oncology Nurs Forum. 2003;30(1):21.

Loimer N, Schmid R. The use of plasma levels to optimize methadone maintenance treatment. Drug Alcohol Depend 1992;30(3):241-246.

Magura S. Rosenblum A. Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med. 2001;68(1):62-74.

Mallinckrodt Inc. Methadose® Oral Concentrate (Methadone hydrochloride oral concentrate USP) [package insert]. St. Louis, MO: Mallinckrodt Inc; 2000.

Mallinckrodt Inc. Methadose® Oral Tablets (Methadone hydrochloride tablets USP; 5, 10, 40 mg) [package inserts]. St. Louis, MO: Mallinckrodt Inc; 1995.

Manfredi PL, Foley KM, Payne R, Inturrisi CE, Houde R. Parenteral methadone: An essential medication for the treatment of pain. In progress, 2003.

Mantelli L, Corti V, Bini R, Cerbai E, Ledda F. Effects of dl-methadone on the response to physiological transmitters and on several functional parameters of the isolated guinea-pig heart. Arch Int Pharmacodyn Ther. 1986;282(2):298-313.

Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: A meta-analysis. Addiction. 1998;93(4):515-532.

Martell BA, Arnstein JH, Ray B, Gourevitch MN. The impact of methadone induction on cardiac conduction in opioid users. Poster presented at: American Association for the Treatment of Opioid Dependence Conference; April 13-16, 2003; Washington, DC. Poster P16.

Mathot F, Kurz X, Noel C, Firket P. Long QTc and psychotropic drugs use. Int J Neuropsychopharmacology. 2002;3(Suppl 1):S173. [Abstract P.02.18.]

McCaffrey BR. Heroin access spurs need for methadone. USA Today. January 25, 1999.

Merrill J. Garvey T, Rosson C. Methadone concentrations taken as indicating deaths due to overdose need to be reviewed [letter]. BMJ. 1996;313:1481.

Mikolaenko I, Robinson A, Davis GG. A review of methadone deaths in Jefferson County, Alabama. J For Med Path. 2002;23(3):299-304.

Milroy CM, Forrest ARW. Methadone deaths: A toxicological analysis. J Clin Pathol. 2000;53:277-281.

Moody DE, Alburges ME, Parker RJ, Collins JM, Strong JM. The involvement of cytochrome P450 3A4 in the N-demethylation of L-_-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab Disp. 1997;25(12):1347-1353.

Nakamura K, Hachey DL, Kreek MJ, Irving CS, Klein PD. Quantitation of methadone enantiomers in humans using stable isotope-labeled [²H₃]-, [²H₅]-, and [²H₈]methadone. J Pharm Sci. 1982;71(1):40-43.

NCHS (National Center for Health Statistics). International Classification of Diseases, Tenth Revision (ICD-10). Available at: http://www.cdc.gov/nchs/about/major/dvs/icd10des.htm. Updated 2002.

Neeleman J, Farrell M. Fatal methadone and heroin overdoses: time trends in England and Wales. Journal of Epidemiology and Community Health. 1997; 51:435-437.

NIDA (National Institute on Drug Abuse). Infectious diseases and drug abuse. NIDA Notes. 1999 (August);14(2):15. NIH pub #99-3478.

NIH (National Institutes of Health). Effective Medical Treatment of Opiate Addiction. NIH Consensus Statement. Bethesda, MD: National Institutes of Health; 1997(Nov 17-19);15(6):1-38. (See also: JAMA. 1998;280:1936-1943.)

Novick DM, Richman BL, Friedman JM, et al. The medical status of methadone maintained patients in treatment for 11-18 years. Drug Alcohol Dep. 1993;33:235-245.

Okruhlica L, Devinsk F, Valentova J, Klempova D. Does therapeutic threshold of methadone concentration in plasma exist? Heroin Add & Rel Clin Probl. 2002;4(1):29-36.

Oliver P, Keen J, Mathers N. Deaths from drugs of abuse in Sheffield 1997-1999: What are the implications for GPs prescribing to heroin addicts? Fam Pract. 2002;19(1):93-94.

ONDCP (Office of National Drug Control Policy). Drug Abuse in America [slide presentation]. Washington, DC: Office of National Drug Control Policy; 2002. Available at: http://www.whitehousedrugpolicy.gov.

ONDCP (Office of National Drug Control Policy). Policy Paper: Opioid Agonist Treatment. Washington, DC: Office of National Drug Control Policy; 1999 (March).

ONDCP (Office of National Drug Control Policy). Methadone Fact Sheet. Washington, DC: Office of National Drug Control Policy; 2000 (April). Available at: http://www.whitehousedrugpolicy.gov.

ONDCP (Office of National Drug Control Policy). President's National Drug Control Strategy 2003. Washington, DC: Office of National Drug Control Policy; 2003 (February). Available at: http://www.whitehousedrugpolicy.gov.

Parrino MW. The renaissance of methadone treatment in America. J Maintenance in the Addictions. 2003;2(1/2):5-17.

Payte JT. A brief history of methadone in the treatment of opioid dependence: a personal perspective. J Psychoactive Drugs. 1991;23(2):103-107.

Payte JT, Khuri ET, Joseph H, Woods J. The methadone maintained patient and the treatment of pain. CDRWG Monograph #2. Chemical Dependency Research Working Group: The New York State Office of Alcoholism and Substance Abuse Services. 1994: 35-40.

Payte JT, Khuri ET. Principles of methadone dose determination. In: Parrino MW. State Methadone Treatment Guidelines. Treatment Improvement Protocol (TIP) Series 1. Rockville, MD: U.S. Department of Health and Human Services; Center for Substance Abuse Treatment;1993a:47-58 DHHS Pub# (SMA) 93-1991.

Payte JT, Khuri ET. Treatment duration and patient retention. In: Parrino MW. State Methadone Treatment Guidelines. Treatment Improvement Protocol (TIP) Series 1. Rockville, MD: U.S. Department of Health and Human Services; Center for Substance Abuse Treatment;1993b:119-124. DHHS Pub# (SMA) 93-1991.

Payte JT, Zweben JE. Opioid maintenance therapies. In: Graham AW, Schultz TK, eds. Principles of Addiction Medicine. 2nd ed. Chevy Chase, MD: American Society of Addiction Medicine, Inc; 1998:557-570.

Perret G, Deglon JJ, Kreek MJ, Ho A, La Harpe R. Lethal methadone intoxications in Geneva, Switzerland, from 1994 to 1998. Addiction. 2000;95(11):1647-1653.

Petry NM, Bickel WK, Badger GJ. A 12-year study (1975 - 1986) of mortality in methadone maintenance patients: Selected demographic characteristics and drug-use patterns of AIDS and non-AIDS-related deaths. Subst Use Misuse. 1998; 33(12):2521-2534.

Prouty RW, Anderson WH. The forensic science implications of site and temporal influences on postmortem blood-drug concentrations. J Forensic Sci. 1990;35(2):243-270.

Rendig SV, Amsterdam EA, Henderson GL, Mason DT. Comparative cardiac contractile actions of six narcotic analgesics: morphine, meperidine, pentazocine, fentanyl, methadone and l-alpha-acetylmethadol (LAAM). J Pharmacol Exp Ther. 1980;215(1):259-265.

Rettig RA, Yarmolonsky A (eds). Federal Regulation of Methadone Treatment. Committee on Federal Regulation of Methadone Treatment; Division of Biobehavioral Sciences and Mental Disorders; Institute of Medicine (IOM). Washington, DC: National Academy Press; 1995.

Robinson AE, Williams FM. The distribution of methadone in man. J Pharm Pharmac. 1971;23:353-358.

Roizin L, Helpern M, Baden M. Methadone fatalities in heroin addicts. Psychiatric Quart. 1972;46(3):393-410.

Rosenblum A, Magura S, Joseph H. Ambivalence toward methadone treatment among intravenous drug users. J Psychoactive Drugs. 1991;23(1):21-

Roxane Laboratories. Dolophine® Hydrochloride (Methadone Hydrochloride Injection, USP) [package insert]. Manufactured by Eli Lilly and Company. Columbus, Ohio: Roxane Laboratories, Inc; May 26, 1995.

Roxane Laboratories. Methadone Hydrochloride IntensolTM (Oral Concentrate, USP 10 mg/mL) [package insert]. Columbus, Ohio: Roxane Laboratories, Inc; Revised February 1998.

Roxane Laboratories. Methadone Hydrochloride Tablets USP [package insert]. Columbus, Ohio: Roxane Laboratories, Inc; Revised December 2000.

SAMHSA (Substance Abuse and Mental Health Services Administration). National Household Survey on Drug Abuse (NHSDA). 2001. Available at http://www.samhsa.gov.

SAMHSA (Substance Abuse and Mental Health Services Administration). The Dawn Report. Narcotic Analgesics. January 2003. Available at http://www.samhsa.gov.

SAMHSA (Substance Abuse and Mental Health Services Administration). Mortality Data From the Drug Abuse Warning Network, 2001. DAWN Series D-23, 2002. DHHS Publication No. (SMA) 03-3781. Available at http://www.samhsa.gov.

Sanford C. Deaths from Unintentional Drug Overdoses in North Carolina, 1997-2001: A DHHS Investigation into Unintentional Poisoning-Related Deaths. NC Injury and Violence Prevention Unit. North Carolina Department of Health and Human Services. September 20, 2002.

Segal RJ, Catherman RL. Methadone - A cause of death. J Forensic Sci. 1974;19(1):64-71.

Seyler DE, Borowitz JL, Maickel RP. Calcium channel blockade by certain opioids. Fundam Appl Toxicol. 1983;3(6):536-542.

Sorg MH. Accidental methadone deaths in Maine 1997-2002. Slide presentation and handout October 7, 2002.

Sorg MH, Greenwald M. Maine Drug-Related Mortality Patterns:1997-2002. State of Maine; December 27, 2002. (Report in cooperation with the Maine Office of the Attorney General and Maine Office of Substance Abuse.)

Sporer KA. Acute heroin overdose. Ann Intern Med. 1999;130:584-590.

Squires T. National confidential enquiry into methadone related deaths (Scotland) 2000. The Scottish Executive, Health Department, Clinical Resource and Audit Group (CRAG Ref 99/05); 2000. Available at: http://www.show.scot.nhs.uk/crag/topics/mhealth/NCEMRD.doc.

Stimmel B, Lipski J, Swartz M, Donoso E. Electrocardiographic changes in heroin, methadone and multiple drug abuse: A postulated mechanism of sudden death in narcotic addicts. Proc Natl Conf Methadone Treat. 1973;1:706-710. Also in: Lipski J, Stimmel B, Donoso E. The effect of heroin and multiple drug abuse on the electrocardiogram. Amer Heart J. 1973;86(5):663-668 [This was an earlier analysis of the same methadone-maintained population].

Stine SM, Meandzija B, Kosten TR. Pharmacologic therapies for opioid addiction. In: Graham AW, Schultz TK, eds. Principles of Addiction Medicine. 2nd ed. Chevy Chase, MD: American Society of Addiction Medicine, Inc; 1998:545-555.

Symanski JD, Gettes LS. Drug effects on the electrocardiogram. A review of their clinical importance. Drugs. 1993;46(2):219-248.

Takehana H, Izumi T. Alcoholic heart disease [Japanese, English abstract]. Nippon Rinsho. 2000;58(1):151-156.

Tomargo J. Drug-induced torsade de pointes: from molecular biology to bedside. Jpn J Pharmacol. 2000;83:1-19.

Valmana A, Oyefeso A, Clancy C, Ghodse H. Methadone-related deaths: Data from 18 coroners' jurisdictions in England. Med Sci Law. 2000;40(1):61-65.

van Laar M, Crutis G, Vicente J, Frost N, Hartnoll R. EMCDDA standard protocol for the EU member states to collect data and report figures for the key indicator drug-related deaths by the standard reitox tables. EMCDDA Scientific Report 20-08-2002. Lisbon Portugal: European Monitoring Centre for Drugs and Drug Addiction; 2002. Available at http://www.emcdda.eu.int.

White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction. 1999;94(7):961-972.

Williamson PA, Foreman KJ, White JM, Anderson G. Methadone-related overdose deaths in South Australia, 1984-1994. Med J Aust. 1997;166:302-305.

Wolff K. Characterization of methadone overdose: Clinical considerations and the scientific evidence. Ther Drug Monit. 2002;24(4):457-470.

Wolf K, Sanderson M, Hay AWM, Ralstrick D. Methadone concentrations in plasma and their relationship to drug dosage. Clin Chem. 1991;37(2):205-209.

Wu C, Fry CH, Henry JA. Membrane toxicity of opioids measured by protozoan motility. Toxicology. 1997a;117:35-44.

Wu C, Fry CH, Henry JA. The mode of action of several opioids on cardiac muscle. Exp Physiol. 1997b;82:261-272.

Wu C, Henry JA. Interaction between ethanol and opioids in a protozoan assay. Hum Exp Toxicol. 1994;13:145-148.

Zador D, Sunjic S, Darke S. Heroin-related deaths in New South Wales, 1992: Toxicological findings and circumstances. Med J Australia. 1996;164:204-207.

Zador D Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995. Addiction. 2000;95(1):77-84.

Zanis DA, Woody GE. One-year mortality rates following methadone treatment discharge. Drug Alcohol Depend. 1998;52(3):257-260.

Zickler P. 33-year study finds lifelong, lethal consequences of heroin addiction. NIDA Notes. 2001;16(4):1. NIH Publication No. 02-3478.

Zweben JE, Payte JT. Methadone maintenance in the treatment of opioid dependence; A current perspective. West J Med. 1990;152:588-599.